Which statement best describes the efficacy assessment in a clinical trial?

• A. Measures used to evaluate the effect of the investigational product
• B. The adverse event reporting timeline
• C. The randomization process
• D. The data management plan

Answer: (A)

Efficacy assessment is about how we determine whether the investigational product has the desired effect. In a trial, this means the predefined measures used to evaluate the product’s effect—what we call the efficacy endpoints and the methods by which they are measured, including timing and analysis plans. These endpoints define what counts as a beneficial outcome and how it will be quantified, so they are specified before the study begins and incorporated into the protocol and statistical analysis plan.

The other aspects mentioned are about different trial components. Adverse event reporting timeline relates to safety monitoring and regulatory reporting of harms, not to whether the drug works. The randomization process ensures unbiased assignment to treatment groups and comparability between groups, which supports valid efficacy comparisons but is not the mechanism by which efficacy is assessed. The data management plan covers how data are collected, stored, cleaned, and protected, ensuring data integrity, but it does not define how the treatment’s effect is measured.